Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

News [2510]

ASCO GU: Long-term data confirms radiotherapy plus anti-androgen therapy substantially improves 10- and 15-year prostate cancer survival rates

ASCO GU: Long-term data confirms radiotherapy plus anti-androgen therapy substantially improves 10- and 15-year...

ASCO GU: Enzalutamide improves survival in men with metastatic castration-resistant prostate cancer

ASCO GU: Enzalutamide improves survival in men with metastatic castration-resistant prostate cancer

ASCO GU: Approximately one in five adult cancer clinical trials fails to complete

ASCO GU: Approximately one in five adult cancer clinical trials fails to complete

Kinase drug targets for prostate cancer are heterogeneous between patients but homogeneous within the same patient

Kinase drug targets for prostate cancer are heterogeneous between patients but homogeneous within the same patient

130,000 people in the UK diagnosed at 65 or over survive cancer for at least a decade

130,000 people in the UK diagnosed at 65 or over survive cancer for at least a decade

Mechanism affecting risk of prostate cancer is found

Mechanism affecting risk of prostate cancer is found

Semantic Web Applications and Tools for Life Sciences (SWAT4LS Workshop in Edinburgh 2013)

Semantic Web Applications and Tools for Life Sciences (SWAT4LS Workshop in Edinburgh 2013)

Computer-controlled table could direct radiotherapy to tumours while sparing vital organs

Computer-controlled table could direct radiotherapy to tumours while sparing vital organs

UK cancer death rates drop by 20 per cent over 20 years

UK cancer death rates drop by 20 per cent over 20 years

Vaccine potential as prostate cancer protein unlocked

Vaccine potential as prostate cancer protein unlocked

More from ecancer